KRAS G13D

News alerts, weekly reports and conference planners

Entrez ID:

3845

Related biomarkers:

‹

›

KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	panitumumab Resistant: A2 - Guideline panitumumab Resistant : A2	panitumumab Resistant: A2 - Guideline panitumumab Resistant : A2
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2
KRAS G13D	Hepatocellular Cancer	KRAS G13D	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G13D	Non Small Cell Lung Cancer	KRAS G13D	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G13D	Non Small Cell Lung Cancer	KRAS G13D	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KRAS G13D	Non Small Cell Lung Cancer	KRAS G13D	Non Small Cell Lung Cancer	ASTX029 Sensitive: C4 – Case Studies ASTX029 Sensitive : C4	ASTX029 Sensitive: C4 – Case Studies ASTX029 Sensitive : C4
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	LY3214996 Sensitive: D – Preclinical LY3214996 Sensitive : D	LY3214996 Sensitive: D – Preclinical LY3214996 Sensitive : D
KRAS G13D	Colon Cancer	KRAS G13D	Colon Cancer	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	BMS-754807 Resistant: D – Preclinical BMS-754807 Resistant : D	BMS-754807 Resistant: D – Preclinical BMS-754807 Resistant : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	cetuximab + vemurafenib Resistant: D – Preclinical cetuximab + vemurafenib Resistant : D	cetuximab + vemurafenib Resistant: D – Preclinical cetuximab + vemurafenib Resistant : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	sunitinib Resistant: D – Preclinical sunitinib Resistant : D	sunitinib Resistant: D – Preclinical sunitinib Resistant : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	trametinib + TPX-0005 Sensitive: D – Preclinical trametinib + TPX-0005 Sensitive : D	trametinib + TPX-0005 Sensitive: D – Preclinical trametinib + TPX-0005 Sensitive : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	P1446A-05 Sensitive: D – Preclinical P1446A-05 Sensitive : D	P1446A-05 Sensitive: D – Preclinical P1446A-05 Sensitive : D
KRAS G13D	Solid Tumor	KRAS G13D	Solid Tumor	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D
KRAS G13D	Solid Tumor	KRAS G13D	Solid Tumor	sotorasib Resistant: D – Preclinical sotorasib Resistant : D	sotorasib Resistant: D – Preclinical sotorasib Resistant : D
KRAS G13D	Pancreatic Adenocarcinoma	KRAS G13D	Pancreatic Adenocarcinoma	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D
KRAS G13D	Colorectal Adenocarcinoma	KRAS G13D	Colorectal Adenocarcinoma	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D

Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.

KRAS G13D

Associations